sesamol has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, L; Hu, G; Hu, X; Jin, H; Ma, X; Ning, S; Zhu, Y | 1 |
| Chen, Y; Ding, L; Hu, G; Hu, X; Ma, X; Ning, S; Wang, J; Zhu, Y | 1 |
2 other study(ies) available for sesamol and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Sesamol inhibits proliferation, migration and invasion of triple negative breast cancer via inactivating Wnt/β-catenin signaling.
Topics: Animals; Benzodioxoles; beta Catenin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epithelial-Mesenchymal Transition; Humans; Mice; Mice, Nude; Phenols; Triple Negative Breast Neoplasms; Wnt Signaling Pathway | 2022 |
Sesamol Epigenetically Induces Estrogen Receptor α Re-expression by Upregulating miR-370-3p in Estrogen Receptor α-Negative Breast Cancer.
Topics: Animals; Benzodioxoles; Breast Neoplasms; Cell Line, Tumor; Endothelial Cells; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; MicroRNAs; Phenols; Triple Negative Breast Neoplasms | 2021 |